The incidence of treatment-related AEs was high (85.0%), as reported for the same treatment combination in a phase I study in patients with NSCLC (74.0%), but grade 3 or higher treatment-related AEs were rare (8.3% in this study and 16% in the phase I NSCLC study).18 The most common AEs were ‘general disorders and administration site conditions’, which is in agreement with the findings of the previous phase II study in patients with melanoma who received MAGE-A3 immunotherapeutic,15 and with other studies with MAGE-A3 vaccination.18–20. The gene discussed is MAGEA3; the disease is non-small cell lung carcinoma.